Nothing Special   »   [go: up one dir, main page]

Latest News for: Gilead Sciences

Edit

Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results

Business Wire 12 Feb 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc ... “Gilead delivered another ...
Edit

Hepatitis B Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by ...

GetNews 12 Feb 2025
Key hepatitis B companies working in the market are Vedanta Biosciences, Gilead Sciences, Dong-A ... In September 2023, Gilead Sciences announced a study of phase 1 clinical trials for GS-2829 and GS-6779.
Edit

S\u0026P 500 ends down as hot US inflation data hints at fewer rate cuts

Usatoday 12 Feb 2025
inflation reading added to worries that the Federal Reserve would not cut interest rates anytime soon, while CVS Health and Gilead Sciences rallied after upbeat quarterly reports ... Gilead Sciences ...
Edit

Experienced life sciences professional appointed CFO at medtech group

The Business Desk 12 Feb 2025
Greetham has over 25 years’ experience in the life sciences sector, ... Prior to this, from 2011, he held finance leadership roles with Thermo Fisher Scientific, Gilead Sciences and Mission Therapeutics.
Edit

COWZ ETF is beating VOO and CALF funds: is it a buy?

Invezz 12 Feb 2025
Qualcomm, AT&T, Gilead Sciences, Valero Energy, and EOG Resources are the biggest companies in the fund ... Gilead is a top firm in the HIV industry, while Schlumberger, which is today known as SLB is the biggest offshore drilling company ... ....
Edit

Stock market today: Wall Street falls in a shaky day after inflation worsens and oil prices ease

The Call 12 Feb 2025
NEW YORK (AP) — After initially reeling on a report showing inflation is worsening for Americans, U.S ... Gilead Sciences rose 6.4% after likewise topping profit expectations, in part because of strength for the pharmaceutical company’s HIV products ... .
Edit

Most of Wall Street sinks after report of worsening inflation

The Los Angeles Times 12 Feb 2025
Most U.S. stocks fell Wednesday after a report showed inflation is unexpectedly worsening for Americans ... Gilead Sciences did just that, and its stock rose 7.5% after the pharmaceutical company topped profit expectations for the latest quarter ... .
Edit

Stock market today: Most of Wall Street sinks after inflation worsens

Odessa American 12 Feb 2025
By STAN CHOE. AP Business Writer. NEW YORK Most U.S ... A barrel of benchmark U.S ... Overall inflation was 3% for U.S ... Gilead Sciences did just that, and its stock rose 7.5% after the pharmaceutical company topped profit expectations for the latest quarter ... .
Edit

Stock market today: Wall Street falls after inflation worsens

The Call 12 Feb 2025
NEW YORK (AP) — U.S. stocks fell after a report said inflation is unexpectedly worsening for Americans ... Gilead Sciences rose 6.4% after likewise topping profit expectations, in part because of strength for the pharmaceutical company’s HIV products ... .
Edit

Fourth Quarter 2024 Resource Book (Gilead Sciences Inc)

Public Technologies 12 Feb 2025
Gilead's Mission ... Welcome to our Gilead Investor Resource Book. This book is a collection of materials intended to streamline the reader's initial review of Gilead materials ... investor_relations@gilead.com ... About Gilead ... Gilead Sciences Inc.
Edit

Fourth Quarter 2024 Summary of Remarks (Gilead Sciences Inc)

Public Technologies 12 Feb 2025
Please refer to our disclosures in the Non-GAAP Financial Information section of our Press Release, issued by Gilead Sciences, Inc ... Gilead ... GILEAD SCIENCES, INC ... GILEAD SCIENCES, INC ... GILEAD SCIENCES, INC ... GILEAD SCIENCES, INC ... Gilead Sciences Inc.
Edit

Fourth Quarter 2024 Prepared Remarks (Gilead Sciences Inc)

Public Technologies 12 Feb 2025
GILEAD SCIENCES FOURTH QUARTER & FULL YEAR 2024 ... Joining Gilead, I look forward to working with Flavius Martin, our Executive Vice President of Research, on some of the most exciting science in the biopharma industry ... Gilead Sciences Inc.

Most Viewed

×